Variability of choroidal and retinal thicknesses in healthy eyes using swept-source optical coherence tomography – implications for designing clinical trials

Albert Caramoy,1 Ludwig M Heindl2 1Eye Center Wolfsburg-Fallersleben, Wolfsburg, 2Department of Ophthalmology, University of Cologne, Cologne, Germany Aim: The aim was to study the variability of choroidal scleral interface (CSI) thickness in healthy subjects and its relevance for designing future...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Caramoy A, Heindl LM
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://doaj.org/article/5bf9f3cf260c46ab833ed43064306302
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:5bf9f3cf260c46ab833ed43064306302
record_format dspace
spelling oai:doaj.org-article:5bf9f3cf260c46ab833ed430643063022021-12-02T00:37:00ZVariability of choroidal and retinal thicknesses in healthy eyes using swept-source optical coherence tomography – implications for designing clinical trials1177-5483https://doaj.org/article/5bf9f3cf260c46ab833ed430643063022017-10-01T00:00:00Zhttps://www.dovepress.com/variability-of-choroidal-and-retinal-thicknesses-in-healthy-eyes-using-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Albert Caramoy,1 Ludwig M Heindl2 1Eye Center Wolfsburg-Fallersleben, Wolfsburg, 2Department of Ophthalmology, University of Cologne, Cologne, Germany Aim: The aim was to study the variability of choroidal scleral interface (CSI) thickness in healthy subjects and its relevance for designing future studies. Methods: A total of 123 volunteers were imaged using swept-source optical coherence tomography. Early treatment diabetic retinopathy grid was used. Results: Mean central retinal thickness was 285.85±14.53 µm and 287.18±12.93 µm, and mean central CSI thickness was 273.94±77.77 µm and 271.19±78.85 µm for the right and left eyes, respectively. Mean retinal and CSI thicknesses correlated negatively with age (p=0.023, r=–0.208 and p<0.0001, r=–0.426, respectively) and axial length (p=0.016, r=–0.220 and p<0.0001, r=–0.504, respectively). To detect a CSI change of at least 112 µm, a sample size of 11 or 36 per group is needed for a single- or double-arm study, respectively (α=0.05, power =0.90, no loss to follow-up, assuming standard deviation in future studies as 100 µm). Conclusion: Future clinical studies using CSI as end point are possible with regard to sample size needed. Keywords: swept-source optical coherence tomography, choroidal thickness, retinal thickness, clinical trialsCaramoy AHeindl LMDove Medical Pressarticleswept-source optical coherence tomographychoroidal thicknessretinal thicknessclinical trialsOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 1835-1839 (2017)
institution DOAJ
collection DOAJ
language EN
topic swept-source optical coherence tomography
choroidal thickness
retinal thickness
clinical trials
Ophthalmology
RE1-994
spellingShingle swept-source optical coherence tomography
choroidal thickness
retinal thickness
clinical trials
Ophthalmology
RE1-994
Caramoy A
Heindl LM
Variability of choroidal and retinal thicknesses in healthy eyes using swept-source optical coherence tomography – implications for designing clinical trials
description Albert Caramoy,1 Ludwig M Heindl2 1Eye Center Wolfsburg-Fallersleben, Wolfsburg, 2Department of Ophthalmology, University of Cologne, Cologne, Germany Aim: The aim was to study the variability of choroidal scleral interface (CSI) thickness in healthy subjects and its relevance for designing future studies. Methods: A total of 123 volunteers were imaged using swept-source optical coherence tomography. Early treatment diabetic retinopathy grid was used. Results: Mean central retinal thickness was 285.85±14.53 µm and 287.18±12.93 µm, and mean central CSI thickness was 273.94±77.77 µm and 271.19±78.85 µm for the right and left eyes, respectively. Mean retinal and CSI thicknesses correlated negatively with age (p=0.023, r=–0.208 and p<0.0001, r=–0.426, respectively) and axial length (p=0.016, r=–0.220 and p<0.0001, r=–0.504, respectively). To detect a CSI change of at least 112 µm, a sample size of 11 or 36 per group is needed for a single- or double-arm study, respectively (α=0.05, power =0.90, no loss to follow-up, assuming standard deviation in future studies as 100 µm). Conclusion: Future clinical studies using CSI as end point are possible with regard to sample size needed. Keywords: swept-source optical coherence tomography, choroidal thickness, retinal thickness, clinical trials
format article
author Caramoy A
Heindl LM
author_facet Caramoy A
Heindl LM
author_sort Caramoy A
title Variability of choroidal and retinal thicknesses in healthy eyes using swept-source optical coherence tomography – implications for designing clinical trials
title_short Variability of choroidal and retinal thicknesses in healthy eyes using swept-source optical coherence tomography – implications for designing clinical trials
title_full Variability of choroidal and retinal thicknesses in healthy eyes using swept-source optical coherence tomography – implications for designing clinical trials
title_fullStr Variability of choroidal and retinal thicknesses in healthy eyes using swept-source optical coherence tomography – implications for designing clinical trials
title_full_unstemmed Variability of choroidal and retinal thicknesses in healthy eyes using swept-source optical coherence tomography – implications for designing clinical trials
title_sort variability of choroidal and retinal thicknesses in healthy eyes using swept-source optical coherence tomography – implications for designing clinical trials
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/5bf9f3cf260c46ab833ed43064306302
work_keys_str_mv AT caramoya variabilityofchoroidalandretinalthicknessesinhealthyeyesusingsweptsourceopticalcoherencetomographyndashimplicationsfordesigningclinicaltrials
AT heindllm variabilityofchoroidalandretinalthicknessesinhealthyeyesusingsweptsourceopticalcoherencetomographyndashimplicationsfordesigningclinicaltrials
_version_ 1718403621379375104